{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:22:27Z","timestamp":1785558147266,"version":"3.56.0"},"reference-count":61,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p>Liposarcoma (LPS) is a common soft tissue sarcoma that encompasses diverse subtypes of well-differentiated\/dedifferentiated, myxoid\/round cell, and pleomorphic LPS. There is heterogeneity among the various LPS types with regard to prognosis, molecular pathogenesis, and response to treatment. Well-differentiated (WDLPS) and dedifferentiated liposarcoma (DDLPS) are most common types, which share common genetic alteration of chromosome 12q13-15 amplification resulting in amplification of oncogenes, including MDM2 (Mouse double minute 2), CDK4 (cyclin-dependent kinase 4), and HMGA2 (High mobility group protein AT-hook 2). Despite sharing the same molecular alteration, DDLPS has a worse prognosis, with a higher recurrence rate and higher propensity for metastases compared to WDLPS. Here we provide an overview of the LPS treatment landscape focusing on recent developments in the treatment of DDLPS with a focus on selinexor. Selinexor, a selective inhibitor of XPO1, was recently evaluated in a phase 3 trial, the first prospective randomized trial in DDLPS, and we discuss its efficacy in context of other available agents for DDLPS.<\/jats:p>","DOI":"10.1177\/17588359221081073","type":"journal-article","created":{"date-parts":[[2022,2,27]],"date-time":"2022-02-27T23:56:16Z","timestamp":1646006176000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0463-1435","authenticated-orcid":false,"given":"Prapassorn","family":"Thirasastr","sequence":"first","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta","family":"Somaiah","sequence":"additional","affiliation":[{"name":"Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0450, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,27]]},"reference":[{"key":"bibr1-17588359221081073","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17082710"},{"key":"bibr2-17588359221081073","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S112580"},{"key":"bibr3-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/538085"},{"key":"bibr4-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26195"},{"key":"bibr5-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3880280"},{"key":"bibr6-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e32834796e6"},{"key":"bibr7-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPLYU89XHSNHQO"},{"key":"bibr8-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102013"},{"key":"bibr9-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.02.006"},{"key":"bibr10-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/148614"},{"key":"bibr11-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6605"},{"key":"bibr12-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-2-2"},{"key":"bibr13-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp004"},{"key":"bibr14-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr485"},{"key":"bibr15-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12132-w"},{"key":"bibr16-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.4117"},{"key":"bibr17-17588359221081073","author":"Thirasastr P","year":"2021","journal-title":"CTOS 2021 annual meeting"},{"key":"bibr18-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01283-0"},{"key":"bibr19-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4734"},{"key":"bibr20-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32117"},{"key":"bibr21-17588359221081073","author":"Gounder MRA","year":"2020","journal-title":"CTOS 2020 annual meeting"},{"key":"bibr22-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30926"},{"key":"bibr23-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103029"},{"key":"bibr24-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70063-4"},{"key":"bibr25-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.07.023"},{"key":"bibr26-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-0705-7"},{"key":"bibr27-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30622-8"},{"key":"bibr28-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5"},{"key":"bibr29-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(01)00398-7"},{"key":"bibr30-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.0264"},{"key":"bibr31-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1658-5"},{"key":"bibr32-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.11015"},{"key":"bibr33-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1274"},{"key":"bibr34-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00442-4"},{"key":"bibr35-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.3949"},{"key":"bibr36-17588359221081073","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13485"},{"key":"bibr37-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00903-4"},{"key":"bibr38-17588359221081073","first-page":"139","volume":"1","author":"Sendino M","year":"2018","journal-title":"Cancer Drug Resist"},{"key":"bibr39-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750158"},{"key":"bibr40-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0550-8"},{"key":"bibr41-17588359221081073","unstructured":"Therapeutics K. Karyopharm announces results from interim analysis of phase 2 SOPRA study evaluating selinexor in relapsed\/refractory acute myeloid leukemia, 2017, https:\/\/www.globenewswire.com\/news-release\/2017\/03\/02\/930523\/0\/en\/Karyopharm-Announces-Results-from-Interim-Analysis-of-Phase-2-SOPRA-Study-Evaluating-Selinexor-in-Relapsed-Refractory-Acute-Myeloid-Leukemia.html"},{"key":"bibr42-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129413"},{"key":"bibr43-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1665664"},{"key":"bibr44-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2169"},{"key":"bibr45-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32292-3"},{"key":"bibr46-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"bibr47-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30120-4"},{"key":"bibr48-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2012.09.002"},{"key":"bibr49-17588359221081073","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7667"},{"key":"bibr50-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-01886-x"},{"key":"bibr51-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.6346"},{"key":"bibr52-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds470"},{"key":"bibr53-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt278"},{"key":"bibr54-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11512"},{"key":"bibr55-17588359221081073","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0284"},{"key":"bibr56-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0231"},{"key":"bibr57-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw368.26"},{"key":"bibr58-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.11509"},{"key":"bibr59-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.11514"},{"key":"bibr60-17588359221081073","unstructured":"Medicine NUSNLo. Treatment of milademetan versus trabectedin in patient with dedifferentiated liposarcoma (MANTRA). ClinicalTrials.gov, 2021, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04979442"},{"key":"bibr61-17588359221081073","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.3016"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221081073","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359221081073","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359221081073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:26:55Z","timestamp":1777588015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359221081073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":61,"alternative-id":["10.1177\/17588359221081073"],"URL":"https:\/\/doi.org\/10.1177\/17588359221081073","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"article-number":"17588359221081073"}}